OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
May 18, 2021
The US Supreme Court has denied a petition by Sandoz, a Novartis company, to review a July 2020 ruling concerning its biosimilar Erelzi (etanercept-szzs), blocking the company from launching the product.
May 07, 2021
Sandoz will soon begin enrolling patients with neovascular age-related macular degeneration in a Phase III study with its proposed biosimilar to aflibercept.
May 01, 2021
Updates to user fee programs that fund FDA operations are being finalized by industry stakeholders for approval by Congress.
February 17, 2021
The EC has granted marketing authorization to Celltrion Healthcare for its adalimumab biosimilar, Yuflyma (CT-P17).
December 11, 2020
Celltrion Healthcare has announced that EMA's CHMP has issued a positive opinion for the marketing authorization of CT-P17—an adalimumab biosimilar.
October 30, 2020
The Center for Drug Evaluation and Research is studying factors that influence the development of generic versions of brand-name drugs.
October 02, 2020
Advances in preclinical development play a crucial role in reducing cost for developing biosimilars.
August 13, 2020
The company has launched its biosimilar rituximab, Ritucad, for the Indian market.
The committee has given a positive opinion on the biosimilar bevacizumab for several cancer indications.
The companies received approval from the EC for Zercepac (HLX02), a biosimilar referencing Roche’s originator biologic, Herceptin (trastuzumab).